Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Efficacy and safety of different doses of subcutaneous galcanezumab in chronic and episodic migraine: A pooled analysis of 3651 patients
Headache
P10 - Poster Session 10 (8:00 AM-9:00 AM)
2-003

Migraine is a severe kind of headache and is represented by 14% of the population and up to 18% of women. Galcanezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptides and is used to prevent migraines. 

In this systematic review and meta-analysis, we aimed to assess the efficacy and safety of galcanezumab doses in chronic and episodic migraines.

In September 2022, we conducted a comprehensive search in five databases, including EMBASE, PubMed, Cochrane Library, Web of Science, and SCOPUS. We appraised each study using the Cochrane risk of bias tool. Our primary outcome was the change in the monthly migraine headache days (MMDs). Data were extracted and analyzed using RevMan version 5.4.

We included eight randomized controlled trials with 3651 migraine patients. In episodic migraine, galcanezumab (120-150 and 240-300mg) showed a significant reduction in MMDs compared to placebo after six months. Also, in chronic migraine, galcanezumab (120mg) reduced MMDs compared to placebo after three months. The analysis was conducted according to each month's records, and the mean difference change ranged from -1.62 to -2.86 (P-value < 0.001). All doses showed a significantly higher rate in ≥50%, ≥75%, and 100% response rates. Regarding safety outcomes, galcanezumab was associated with injection site-related complications such as pruritis, reaction, swelling, or erythema. In contrast, the two groups showed no difference regarding any adverse or serious adverse events, upper respiratory tract infection, oropharyngeal pain, injection site pain, back pain, sinusitis, and diarrhea.

Subcutaneous galcanezumab reduced MMDs and increased response rates in chronic and episodic migraine patients. It is generally safe except for injection-related complications.

Authors/Disclosures
Mohamed *use 351751 Zaazouee
PRESENTER
Dr. Zaazouee has nothing to disclose.
Ahmed Bostamy Elsnhory, Jr. (Non) Mr. Elsnhory has nothing to disclose.
Rokaya Y. Ebrahim (Alexandria University) Ms. Ebrahim has nothing to disclose.
Ghaidaa Alaraj, MD (Faculty of medicine) Dr. Alaraj has nothing to disclose.
Ahmed Saad Dr. Saad has nothing to disclose.
Ibram Zaki Dr. Zaki has nothing to disclose.
Mustafa Hussein Ali, PhD (Altaf University College) Mr. Ali has nothing to disclose.
Omar Khaled Fahmy Fawy, MD Dr. Fahmy Fawy has nothing to disclose.
Hadi F. Ahmed (Alrai Medical) Dr. Ahmed has nothing to disclose.
Mohamed Elshennawy, MD Dr. Elshennawy has nothing to disclose.
Mohammed Eleyan, Jr., PhD Dr. Eleyan has nothing to disclose.
Ziad Alahmad Dr. Alahmad has nothing to disclose.
Reem Ibrahim Abo Hamra, Other (.) Dr. Abo Hamra has nothing to disclose.
Hazem Gamal AbuEl-Enien, Sr., Other (Memac Ogilvy-Health and Wellness department) Dr. AbuEl-Enien has nothing to disclose.
Rasha Abdo Elromely, Other (No) Dr. Elromely has nothing to disclose.
Alaa Elshanbary, MBBS Dr. Elshanbary has nothing to disclose.